Recomendation_2017_30_10_2017_HR

ДИАГНОСТИКАИЛЕЧЕНИЕФИБРИЛЛЯЦИИПРЕДСЕРДИЙ

522.BandiniA,GoliaP,CaroliE,BiancoliS,GalvaniM. Atrialfibrillationafter typicalatrialflutterablation:along-termfollow-up.JCardiovascMed (Hagerstown)2011;12:110–115.

523.DewlandTA,GliddenDV,MarcusGM.Healthcareutilizationandclinical outcomesaftercatheterablationofatrialflutter.PLoSOne2014;9: e100509.

524.InstituteofMedicineCommitteeonQualityofHealthCareinAmerica. CrossingtheQualityChasm:ANewHealthSystemforthe21stCentury. Washington(DC):NationalAcademiesPress(US);2001.

525.BodenheimerT,WagnerEH,GrumbachK. Improvingprimarycarefor patientswithchronicillness.JAMA2002;288:1775–1779.

526.McCabePJ.Self-managementofatrialfibrillation:anewfrontierfor nursingresearch.ProgCardiovascNurs2008;23:37–40.

527.LipGY,KamathS,JafriM,MohammedA,BarefordD. Ethnicdifferences inpatientperceptionsofatrialfibrillationandanticoagulationtherapy: theWestBirminghamAtrialFibrillationProject.Stroke2002;33:238– 242.

528.HendriksJM,CrijnsHJ,TielemanRG,VrijhoefHJ.Theatrialfibrillation knowledgescale:development,validationandresults.IntJCardiol 2013;168:1422–1428.

529.McCabe PJ. What patients want and need to know about atrial fibrillation.JMultidiscipHealthc2011;4:413–419.

530.LorigKR,HolmanH. Self-managementeducation:history,definition, outcomes,andmechanisms.AnnBehavMed2003;26:1–7.

531.Alonso-Coello P, Montori VM, Sola I, Schunemann HJ, Devereaux P, Charles C, Roura M, Diaz MG, Souto JC, Alonso R, Oliver S, Ruiz R,Coll-VinentB,DiezAI,Gich I,GuyattG. Valuesandpreferencesin oralanticoagulationinpatientswithatrialfibrillation,physicians’and patients’perspectives:protocolforatwo-phasestudy.BMCHealth ServRes2008;8:221.

532.FabritzL,GuaschE,AntoniadesC,etal.Expertconsensusdocument: Definingthemajorhealthmodifierscausingatrialfibrillation:aroadmap tounderpinpersonalizedpreventionandtreatment.NatRevCardiol 2016;13:230–237.

533.VanWagoner DR, Piccini JP, Albert CM, et al. Progress toward the preventionandtreatmentofatrialfibrillation:AsummaryoftheHeart RhythmSocietyResearchForumontheTreatmentandPrevention ofAtrialFibrillation,Washington,DC,December9–10,2013.Heart Rhythm2015;12:e5–e29.

691

ГЛАВА4

534.SvennbergE,EngdahlJ,Al-KhaliliF,FribergL,Frykman V,Rosenqvist M. MassScreeningforUntreatedAtrialFibrillation:TheSTROKESTOP Study.Circulation2015;131:2176–2184.

535.Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: epidemiology, pathophysiology, presentation,andprognosis.NatRevCardiol2016;13:321–332.

536.Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Pokushalov E, Kische S, Schmitz T, Stein KM, Bergmann MW, EWOLUTIONinvestigators.Implantsuccessandsafetyofleftatrial appendage closure with the WATCHMAN device: peri-procedural outcomesfromtheEWOLUTIONregistry.EurHeartJ;doi:10.1093/ eurheartj/ehv730.2016.

537.KuramatsuJB,GernerST,SchellingerPDetal.Anticoagulantreversal, blood pressure levels, and anticoagulant resumption in patients withanticoagulationrelatedintracerebralhemorrhage.JAMA2015; 313:824–836.

538.Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on RecurrentStroke,Mortality,andBleeding:ANationwideCohortStudy. Circulation2015;132:517–525.

539.vanNieuwenhuizenKM,vanderWorpHB,AlgraA,KappelleLJ,Rinkel GJ,vanGelderIC,SchutgensRE,KlijnCJ,APACHE-AFInvestigators. ApixabanversusAntiplateletdrugsornoantithromboticdrugsafter anticoagulation-associatedintraCerebralHaEmorrhageinpatients withAtrialFibrillation(APACHE-AF):studyprotocolforarandomised controlledtrial.Trials2015;16:393.

540.Nuotio I,HartikainenJE,GronbergT,BiancariF,AiraksinenKE.Time to cardioversion for acute atrial fibrillation and thromboembolic complications.JAMA2014;312:647–649.

541.GronbergT,Nuotio I,NikkinenM,YlitaloA,VasankariT,HartikainenJE, AiraksinenKE.Arrhythmiccomplicationsafterelectricalcardioversion ofacuteatrialfibrillation:theFinCVstudy.Europace2013;15:1432– 1435.

542.Tse HF, Lau CP. Does sinus rhythm beget sinus rhythm? Effects of promptcardioversiononthefrequencyandpersistenceofrecurrent atrialfibrillation.CardElectrophysiolRev2003;7:359–365.

692

ДИАГНОСТИКАИЛЕЧЕНИЕФИБРИЛЛЯЦИИПРЕДСЕРДИЙ

543.VanGelderIC,HemelsME.Theprogressivenatureofatrialfibrillation: a rationale for early restoration and maintenance of sinus rhythm. Europace2006;8:943–949.

544.LiuZJ,FuWG,GuoZY,ShenLG,ShiZY,LiJH.Updatedsystematic review and meta-analysis of randomized clinical trials comparing carotidarterystentingandcarotidendarterectomyinthetreatment ofcarotidstenosis.AnnVascSurg2012;26:576–590.

545.TaylorDW,BarnettHJM,HaynesRB,FergusonGG,SackettDL,Thorpe KE,SimardD,SilverFL,Hachinski V,ClagettGP,barnesR,SpenceJD, ASAandCarotidEndarterectomy(ACE)trialcollaborators.Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy:arandomisedcontrolledtrial.Lancet1999;353:2179– 2184.

546.WatanabeM,ChaudhrySA,AdilMM,AlqadriSL,MajidiS,SemaanE, Qureshi AI. The effect of atrial fibrillation on outcomes in patients undergoing carotid endarterectomy or stent placement in general practice.JVascSurg2015;61:927–932.

547.Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W,Becker RC, NesselCC,MahaffeyKW,Fox KA, CaliffRM,ROCHETAFSteeringCommittee&Investigators.Clinical characteristicsandoutcomeswithrivaroxabanvs.warfarininpatients with non-valvular atrial fibrillation but underlying native mitral and aorticvalvediseaseparticipatingintheROCKETAFtrial.EurHeartJ 2014;35:3377–3385.

548.Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D, Angoulvant D, Lip GY, Fauchier L. Prognostic value of CHA2DS2-VAScscoreinpatientswith‘non-valvularatrialfibrillation’ andvalvularheartdisease:theLoireValleyAtrialFibrillationProject. EurHeartJ2015;36:1822–1830.

549.Breithardt G, Baumgartner H. Valvular heart disease among nonvalvular atrial fibrillation: a misnomer, in search of a new term. Eur HeartJ2015;36:1794–1797.

550.ClinicalTrials.gov.RateControlTherapyEvaluationinPermanentAtrial Fibrillation(RATE-AF).https://clinicaltrials.gov/ct2/show/NCT02391337 (5May2016).

551.KirchhofP,Calkins H. Catheter ablationin patientswith persistent atrialfibrillation.EurHeartJ2016;10.1093/eurheartj/ehw260.

693

ГЛАВА4

552.WolfRK,SchneebergerEW,OsterdayR,MillerD,MerrillW,FlegeJBJr, GillinovAM.Video-assistedbilateralpulmonaryveinisolationandleft atrialappendageexclusionforatrialfibrillation.JThoracCardiovasc Surg2005;130:797–802.

553.Yilmaz A, Van Putte BP, Van Boven WJ. Completely thoracoscopic bilateralpulmonaryveinisolationandleftatrialappendageexclusion foratrialfibrillation.JThoracCardiovascSurg2008;136:521–522.

554.Whitlock R, Healey J, Vincent J, Brady K, Teoh K, Royse A, Shah P, GuoY,AlingsM,FolkeringaRJ,PaparellaD,ColliA,MeyerSR,Legare JF, Lamontagne F, ReentsW, Boning A, Connolly S. Rationale and designoftheLeftAtrialAppendageOcclusionStudy(LAAOS)III.Ann CardiothoracSurg2014;3:45–54.

555.SalzbergSP,PlassA,EmmertMY,DesbiollesL,AlkadhiH,Grunenfelder J,GenoniM. Leftatrialappendageclipocclusion:earlyclinicalresults. JThoracCardiovascSurg2010;139:1269–1274.

556.PapworthHospitalNHSFoundationTrust.Arandomisedcontrolled trial to investigate the clinical and cost effectiveness of adding an ablationdevice-basedmazeprocedureasaroutineadjuncttoelective cardiacsurgeryforpatientswithpre-existingatrialfibrillation.http:// www.isrctn.com/ISRCTN82731440.

557.Mikhaylov EN, Lebedev DS, Pokushalov EA, Davtyan KV, Ivanitskii EA, Nechepurenko AA, Kosonogov AY, Kolunin GV, Morozov IA, TermosesovSA,MaykovEB,KhomutininDN,EreminSA,MayorovIM, RomanovAB,Shabanov VV,Shatakhtsyan V,Tsivkovskii V,Revishvili ASh,ShlyakhtoEV.OutcomesofCryoballoonAblationinHigh-and Low-VolumeAtrialFibrillationAblationCentres:ARussianPilotSurvey. Biomed Res Int 2015;2015:591603.Di Biase L, Briceno DF, Triverdi C,et al.Istranseshphagealechocardiogrammandatory inpatients undergoingablationofatrialfibrillationwithuninterruptednoveloral anticoagulants?Resultsfromaprospectivemulticenterregistry.Heart Rhythm,2016,13(6),1197–1202.

558.ZouH,ZhangY,TongJ,LiuZ.Multidetectorcomputedtomographyfor detectingleftatrial/leftatrialappendagethrombus:ameta-analysis. InternalMedicineJournal,2015:Vol.45(10),1044–1053.

559.BilchickKC,MealorA,GonzalezJ,etal.EffectivenessofIntegrating DelayedComputedTomographyAngiographyImagingforLeftAtrial AppendageThrombusExclusionintotheCareofPatientsUndergoing AblationofAtrialFibrillation.HeartRhythm.2016January;13(1):12–19.

694

ДИАГНОСТИКАИЛЕЧЕНИЕФИБРИЛЛЯЦИИПРЕДСЕРДИЙ

560.TeunissenC,HabetsJ,VelthuisBK,CramerMJ,·LohP. Double-contrast, single-phasecomputedtomographyangiographyforrulingoutleft atrial appendage thrombus prior to atrial fibrillation ablation. Int J CardiovascImaging,2017,33(1):121–128.

561.Nuotio I,HartikainenJE,GronbergT,BiancariF,AiraksinenKE.Time to cardioversion for acute atrial fibrillation and thromboembolic complications.JAMA2014;312:647–649.

562.JaberWA,PriorDL,ThamilarasanM,etal.Efficacyofanticoagulationin resolvingleftatrialandleftatrialappendagethrombi:atransesophageal echocardiographicstudy.AmHeartJ.2000;140:150–6.

563.YadlapatiA,GrohC,PassmanR. Safetyofshort-termuseofdabigatran orrivaroxabanfordirect-currentcardioversioninpatientswithatrial fibrillationandatrialflutter.Am. J. Cardiol.2014;113(8):1362–3.

564.Cozma D, Streian C G, Vacarescu C, Mornos C. Back to sinus rhythm from atrial flutter or fibrillation: dabigatran is safe without transoesophagealcontrol.KardiolPol.2016;74(5):425–30.

565.JohanssonAK,JuhlinT,EngdahlJ,etal.Isonemonthtreatmentwith dabigatranbeforecardioversionofatrialfibrillationsufficienttoprevent thromboembolism?.Europace.2015;17(10):1514–7.

566.PallisgaardJL,LindhardtTB,HansenML,etal.CardioversionandRisk of Adverse Events with Dabigatran versus Warfarin-A Nationwide CohortStudy.PLoSONE.2015;10(10).

567.NagarakantiR,EzekowitzMD,OldgrenJ,YangS,ChernickM,Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation:ananalysisofpatientsundergoingcardioversion.Circulation 2011;123:131–136.

568.Gagliardi L, Guerbaai RA, Marliere S, et al. Coronary embolization followingelectricalcardioversioninapatienttreatedwithdabigatran. Int.J. Cardiol.2014;175(3):571–2.

569.MitamuraH,NagaiT,WatanabeA,etal.Leftatrialthrombusformation andresolutionduringdabigatrantherapy:AJapaneseHeartRhythm Societyreport.JArrhythm.2015;31(4):226–31.

570.Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes following cardioversionandatrial fibrillationablation inpatientstreated with rivaroxabanandwarfarinintheROCKETAFTrial.JAmCollCardiol.2013; 61:1998–2006.

571.Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M,

695

ГЛАВА4

Lanius V,MengIL,WildgooseP,vanEickelsM,HohnloserSH,X–VeRT Investigators.Rivaroxabanvs.vitaminKantagonistsforcardioversion inatrialfibrillation.EurHeartJ2014;35:3346–3355.

572.A. Plittetal:Cardioversionwithedoxabanvswarfarin.Clin.Cardiol. 39,6,345–346(2016).

573.AGoette,JL Merino,MDEzekowitz,etal.Edoxabanversusenoxaparin– warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF):arandomised,open-label,phase3btrial.Lancet.2016 Oct22;388(10055):1995–2003.

574.Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and safety of apixaban in patients following cardioversion for atrial fibrillation: insightsfromtheARISTOTLEtrial(ApixabanforReductioninStroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol.2014;63:1082–7.

575.Renda G, Ricci F, De Caterina R. Non-vitamin K Antagonist Oral AnticoagulantsforCardioversioninAtrialFibrillation—​AnUpdated Meta-analysis,TheAmericanJournalofMedicine(2016),doi:10.1016/j. amjmed.2016.09.023.

576.Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W,OldgrenJ,SinnaeveP,CammAJ,KirchhofP. UpdatedEuropean HeartRhythmAssociationPracticalGuideontheuseofnon-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.Europace2015;17:1467–1507

577.KleinAL,GrimmRA,MurrayRD,Apperson-HansenC,AsingerRW,Black IW,DavidoffR,ErbelR,HalperinJL,OrsinelliDA,PorterTR,Stoddard MF.Useoftransesophagealechocardiographytoguidecardioversion inpatientswithatrialfibrillation.NEnglJMed2001;344:1411–1420.

578.Weigner MJ, Thomas LR, Patel U, et al. Early cardioversion of atrial fibrillationfacilitatedbytransesophagealechocardiography:shortterm safety and impact on maintenance of sinus rhythm at 1 year. AmJMed.2001;110:694–702.

579.CTJanuary,LSWann,JS.Alpert,etal.2014AHA/ACC/HRSGuideline fortheManagementofPatientsWithAtrialFibrillation.Circulation. 2014;130:e199-e267.

580.AiraksinenKE,GronbergT,Nuotio I,NikkinenM,YlitaloA,BiancariF, HartikainenJE.Thromboemboliccomplicationsaftercardioversion ofacuteatrialfibrillation:theFinCV(FinnishCardioVersion)study.J AmCollCardiol2013;62:1187–1192.

696

ДИАГНОСТИКАИЛЕЧЕНИЕФИБРИЛЛЯЦИИПРЕДСЕРДИЙ

581.Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patientswithatrialfibrillationlastinglessthan48hours.AnnIntern Med.1997;126:615–20.

582.AdN,HenryL,HuntS. Currentroleforsurgeryintreatmentoflone atrialfibrillation.SeminThoracCardiovascSurg2012;24:42–50.

583.Weimar T, Schena S, Bailey MS, Maniar HS, Schuessler RB, Cox JL, DamianoRJJr. Thecox-mazeprocedureforloneatrialfibrillation:a single-centerexperienceover2decades.CircArrhythmElectrophysiol 2012;5:8–14.

584.Blomstrom-LundqvistC,JohanssonB,BerglinE,NilssonL,Jensen SM,ThelinS,HolmgrenA,EdvardssonN,KallnerG,BlomstromP.A randomizeddouble-blindstudyofepicardialleftatrialcryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery:theSWEDishMulticentreAtrialFibrillationstudy(SWEDMAF). EurHeartJ2007;28:2902–2908.

585.ChevalierP,LeizoroviczA,MaureiraP,CarteauxJP,CorbineauH,Caus T,DeBreyneB,MabotP,DechillouC,DeharoJC,BarryS,TouboulP, VillemotJP,ObadiaJF.Leftatrialradiofrequencyablationduringmitral valvesurgery:aprospectiverandomizedmulticentrestudy(SAFIR). ArchCardiovascDis2009;102:769–775.

586.ChengDC,AdN,MartinJ,BerglinEE,ChangBC,DoukasG,Gammie JS,NittaT,WolfRK,PuskasJD.Surgicalablationforatrialfibrillation incardiacsurgery:ameta-analysisandsystematicreview.Innovations (Phila)2010;5:84–96.

587.BarnettSD,Ad N. Surgicalablationastreatmentfortheelimination ofatrialfibrillation:ameta-analysis.JThoracCardiovascSurg2006; 131:1029–1035.

588.AdN,HenryL,HuntS,HolmesSD.Doweincreasetheoperativerisk byaddingtheCoxMaze IIIproceduretoaorticvalvereplacementand coronary artery bypass surgery? J Thorac Cardiovasc Surg 2012; 143:936–944.

589.Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, Hao S, Themistoclakis S, Fanelli R, Potenza D, Massaro R,WazniO,SchweikertR,SalibaW,WangP,Al-AhmadA,BeheiryS, SantarelliP,StarlingRC,DelloRussoA,PelargonioG,BrachmannJ, Schibgilla V,BonsoA,CasellaM,RavieleA,HaissaguerreM,NataleA, PABA-CHFInvestigators.Pulmonary-veinisolationforatrialfibrillation inpatientswithheartfailure.NEnglJMed2008;359:1778–1785.

697

ГЛАВА4

590.DiBiaseL,MohantyP,MohantyS,SantangeliP,TrivediC,Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A, Casella M, PelargonioG,NarducciML,SchweikertR,NeuzilP,SanchezJ,Horton R,BeheiryS,HongoR,HaoS,RossilloA,ForleoG,TondoC,Burkhardt JD,HaissaguerreM,NataleA. Ablationvs.AmiodaroneforTreatment of Persistent Atrial Fibrillation in Patients With Congestive Heart FailureandanImplantedDevice:ResultsFromtheAATACMulticenter Randomized Trial. Circulation; doi:10.1161/CIRCULATIONAHA.115.019406.Publishedonlineaheadofprint30March2016.

591.Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, GoromonziF,Sawhney V,DuncanE,PageSP,UllahW,UnsworthB, MayetJ,DhinojaM,EarleyMJ,SportonS,SchillingRJ.Arandomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol2014;7:31–38.

592.MacDonaldMR,ConnellyDT,HawkinsNM,SteedmanT,PayneJ,Shaw M, Denvir M, Bhagra S, Small S, Martin W, McMurray JJ, Petrie MC. Radiofrequencyablationforpersistentatrialfibrillationinpatientswith advancedheartfailureandsevereleftventricularsystolicdysfunction: arandomisedcontrolledtrial.Heart2011;97:740–747.

593.Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P, Ailawadi G, Bouchard D, Smith PK, Mack MJ, Acker MA, MullenJC,RoseEA,ChangHL,PuskasJD,CoudercJP,GardnerTJ, VargheseR,HorvathKA,BollingSF,MichlerRE,GellerNL,Ascheim DD,MillerMA,BagiellaE,MoqueteEG,WilliamsP,Taddei-PetersWC, O’GaraPT,BlackstoneEH,ArgenzianoM,CTSNInvestigators.Surgical ablationofatrialfibrillationduringmitral-valvesurgery.NEnglJMed 2015;372:1399–1409.

594.CoxJL,SchuesslerRB,D’AgostinoHJJr,StoneCM,ChangBC,Cain ME,CorrPB,BoineauJP.Thesurgicaltreatmentofatrialfibrillation.III. Developmentofadefinitivesurgicalprocedure.JThoracCardiovasc Surg1991;101:569–583.

595.Stulak JM, SuriRM,BurkhartHM, Daly RC,DearaniJA, GreasonKL, JoyceLD,ParkSJ,SchaffHV.Surgicalablationforatrialfibrillationfor twodecades:aretheresultsofnewtechniquesequivalenttotheCox mazeIIIprocedure?JThoracCardiovascSurg2014;147:1478–1486.

596.Basu S, Nagendran M, Maruthappu M. How effective is bipolar radiofrequencyablationforatrialfibrillationduringconcomitantcardiac surgery?InteractCardiovascThoracSurg2012;15:741–748.

698

ДИАГНОСТИКАИЛЕЧЕНИЕФИБРИЛЛЯЦИИПРЕДСЕРДИЙ

597.LinZ,ShanZG,LiaoCX,ChenLW.Theeffectofmicrowaveandbipolar radiofrequency ablation in the surgical treatment of permanent atrialfibrillationduringvalvesurgery.ThoracCardiovascSurg2011; 59:460–464.

598.McCarthyPM,KruseJ,ShalliS,IlkhanoffL,GoldbergerJJ,KadishAH, AroraR,LeeR. Wheredoesatrialfibrillationsurgeryfail?Implications forincreasingeffect-ivenessofablation.JThoracCardiovascSurg 2010;139:860–867.

599.AbreuFilhoCA,LisboaLA,DallanLA,SpinaGS,GrinbergM,Scanavacca M, Sosa EA, Ramires JA, Oliveira SA. Effectiveness of the maze procedureusingcooled-tipradiofrequencyablationinpatientswith permanent atrial fibrillation and rheumatic mitral valve disease. Circulation2005;112:I20–25.

600.Blomstrom-LundqvistC,JohanssonB,BerglinE,NilssonL,Jensen SM,ThelinS,HolmgrenA,EdvardssonN,KallnerG,BlomstromP.A randomizeddouble-blindstudyofepicardialleftatrialcryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery:theSWEDishMulticentreAtrialFibrillationstudy(SWEDMAF). EurHeartJ2007;28:2902–2908.

601.ChevalierP,LeizoroviczA,MaureiraP,CarteauxJP,CorbineauH,Caus T,DeBreyneB,MabotP,DechillouC,DeharoJC,BarryS,TouboulP, VillemotJP,ObadiaJF.Leftatrialradiofrequencyablationduringmitral valvesurgery:aprospectiverandomizedmulticentrestudy(SAFIR). ArchCardiovascDis2009;102:769–775.

602.DenekeT,KhargiK,GrewePH,LaczkovicsA,vonDryanderS,LawoT, MullerKM,LemkeB. EfficacyofanadditionalMAZEprocedureusing cooled-tip radiofrequency ablation in patients with chronic atrial fibrillationandmitralvalvedisease.Arandomized,prospectivetrial. EurHeartJ2002;23:558–566.

603.DoukasG,SamaniNJ,AlexiouC,OcM,ChinDT,StaffordPG,NgLL, SpytTJ.Leftatrialradiofrequencyablationduringmitralvalvesurgery forcontinuousatrialfibrillation:arandomizedcontrolledtrial.JAMA 2005;294:2323–2329.

604.SchuetzA,SchulzeCJ,SarvanakisKK,MairH,PlazerH,KilgerE,Reichart B,WildhirtSM.Surgicaltreatmentofpermanentatrialfibrillationusing microwaveenergyablation:aprospectiverandomizedclinicaltrial.Eur JCardiothoracSurg2003;24:475–480.

605.Liu X,TanHW,WangXH,ShiHF,LiYZ,LiF,ZhouL,GuJN.Efficacyof catheterablationandsurgicalCryoMazeprocedureinpatientswith

699

ГЛАВА4

long-lastingpersistentatrialfibrillationandrheumaticheartdisease: arandomizedtrial.EurHeartJ2010;31:2633–2641.

606.ChengDC,AdN,MartinJ,BerglinEE,ChangBC,DoukasG,Gammie JS,NittaT,WolfRK,PuskasJD.Surgicalablationforatrialfibrillation incardiacsurgery:ameta-analysisandsystematicreview.Innovations (Phila)2010;5:84–96.

607.BarnettSD,Ad N. Surgicalablationastreatmentfortheelimination ofatrialfibrillation:ameta-analysis.JThoracCardiovascSurg2006; 131:1029–1035.

608.Ad N, Henry L, Massimiano P, Pritchard G, Holmes SD. The state of surgical ablation for atrial fibrillation in patients with mitral valve disease.CurrOpinCardiol2013;28:170–180.

609.Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB Jr,O’BrienSM,GriffithBP,PetersonED.Atrialfibrillationcorrection surgery: lessons from the Society of Thoracic Surgeons National CardiacDatabase.AnnThoracSurg2008;85:909–914.

610.HuffmanMD,KarmaliKN,BerendsenMA,AndreiA-C,KruseJ,McCarthy PM, Malaisrie CS. Concomitant atrial fibrillation surgery for people undergoingcardiacsurgery.CochraneDatabaseofSystematicReviews 2016;8:CD011814.DOI:10.1002/14651858.CD011814.pub2.

611.Chen MC, Chang JP, Chang HW. Preoperative atrial size predicts thesuccessofradiofrequencymazeprocedureforpermanentatrial fibrillationinpatientsundergoingconcomitantvalvularsurgery.Chest 2004;125:2129–2134.

612.SunderlandN,MaruthappuM,NagendranM. Whatsizeofleftatrium significantlyimpairsthesuccessofmazesurgeryforatrialfibrillation? InteractCardiovascThoracSurg2011;13:332–338.

613.ChaiyarojS,NgarmukosT,LertsithichaiP. Predictorsofsinusrhythm afterradiofrequencymazeandmitralvalvesurgery.AsianCardiovasc ThoracAnn2008;16:292–297.

614.Gillinov AM, Bhavani S, Blackstone EH, Rajeswaran J, Svensson LG,Navia JL,PetterssonBG, Sabik JFIII,SmediraNG, MihaljevicT, McCarthy PM, Shewchik J, Natale A. Surgery for permanent atrial fibrillation:impactofpatientfactorsandlesionset.AnnThoracSurg 2006;82:502–513;discussion513–504.

615.Beukema WP, Sie HT, Misier AR, Delnoy PP, Wellens HJ, Elvan A. Predictive factors of sustained sinus rhythm and recurrent atrial fibrillation after a radiofrequency modified Maze procedure. Eur J CardiothoracSurg2008;34:771–775.

700